- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR inhibitors in urinary bladder cancer
Authors
Keywords
mTOR, Urinary bladder cancer, Sirolimus, Everolimus, Temsirolimus
Journal
TUMOR BIOLOGY
Volume 37, Issue 9, Pages 11541-11551
Publisher
Springer Nature
Online
2016-05-27
DOI
10.1007/s13277-016-5083-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC).
- (2017) L. S. Blaszkowsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Combining Rapamycin and Resveratrol on Apoptosis and Growth of TSC2-Deficient Xenograft Tumors
- (2015) Anya Alayev et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
- (2015) S Hafeez et al. BRITISH JOURNAL OF CANCER
- Emerging therapeutic targets in bladder cancer
- (2015) Benedito A. Carneiro et al. CANCER TREATMENT REVIEWS
- Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise
- (2015) J. Kim et al. CLINICAL CANCER RESEARCH
- Molecular markers in bladder cancer: Novel research frontiers
- (2015) Francesca Sanguedolce et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Targeting the genetic alterations of the PI3K–AKT–mTOR pathway: Its potential use in the treatment of bladder cancers
- (2015) Nadine Houédé et al. PHARMACOLOGY & THERAPEUTICS
- Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1
- (2015) Naotaka Sekiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted Therapy in Advanced Bladder Cancer
- (2015) Emmet J. Jordan et al. UROLOGIC CLINICS OF NORTH AMERICA
- Surgical Advances in Bladder Cancer
- (2015) David C. Johnson et al. UROLOGIC CLINICS OF NORTH AMERICA
- Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review
- (2015) Vishal Vashistha et al. BMC CANCER
- A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
- (2015) Francesca Chiarini et al. Oncotarget
- Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades
- (2015) James Andrew McCubrey et al. Oncotarget
- Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
- (2014) Pasquale Cirone et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Current Models of Mammalian Target of Rapamycin Complex 1 (mTORC1) Activation by Growth Factors and Amino Acids
- (2014) Xu Zheng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Circulating miRNAs in cancer: from detection to therapy
- (2014) Wen-Tao Wang et al. Journal of Hematology & Oncology
- Control of Paip1-Eukayrotic Translation Initiation Factor 3 Interaction by Amino Acids through S6 Kinase
- (2014) Y. Martineau et al. MOLECULAR AND CELLULAR BIOLOGY
- The mTOR Pathway Controls Cell Proliferation by Regulating the FoxO3a Transcription Factor via SGK1 Kinase
- (2014) Shunsuke Mori et al. PLoS One
- Bladder Cancer Biomarker Discovery Using Global Metabolomic Profiling of Urine
- (2014) Bryan M. Wittmann et al. PLoS One
- Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
- (2014) Athanasia Pavlidou et al. TheScientificWorldJOURNAL
- Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer
- (2014) Rosário Pinto-Leite et al. TUMOR BIOLOGY
- The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
- (2014) Tasuku Matsuoka et al. Cancers
- Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma
- (2013) Karen-Lise G. Spindler et al. ACTA ONCOLOGICA
- Phase II study of everolimus in metastatic urothelial cancer
- (2013) Matthew I. Milowsky et al. BJU INTERNATIONAL
- Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study
- (2013) Ágnes Márk et al. BMC CANCER
- Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
- (2013) Dipti K. Pawaskar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience
- (2013) J. C. Yao et al. CANCER RESEARCH
- Differentiating mTOR inhibitors in renal cell carcinoma
- (2013) Sumanta K. Pal et al. CANCER TREATMENT REVIEWS
- mTORC1 Inhibitors Suppress Meningioma Growth in Mouse Models
- (2013) D. Pachow et al. CLINICAL CANCER RESEARCH
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- Biomarkers in bladder cancer: Translational and clinical implications
- (2013) Liang Cheng et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
- (2013) Rhonda L Bitting et al. ENDOCRINE-RELATED CANCER
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
- (2013) Marko Babjuk et al. EUROPEAN UROLOGY
- PI3K/AKT pathway activation in bladder carcinogenesis
- (2013) Julien Calderaro et al. INTERNATIONAL JOURNAL OF CANCER
- Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics
- (2013) Naif AlQurashi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Reprogramming of the MicroRNA Transcriptome Mediates Resistance to Rapamycin
- (2013) Hana Totary-Jain et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mutations in Critical Domains Confer the HumanmTORGene Strong Tumorigenicity
- (2013) Avaniyapuram Kannan Murugan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Signal integration by mTORC1 coordinates nutrient input with biosynthetic output
- (2013) Christian C. Dibble et al. NATURE CELL BIOLOGY
- Antitumor Effect of Everolimus in Preclinical Models of High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas
- (2013) Julien Bollard et al. NEUROENDOCRINOLOGY
- Expression Microarray Meta-Analysis Identifies Genes Associated with Ras/MAPK and Related Pathways in Progression of Muscle-Invasive Bladder Transition Cell Carcinoma
- (2013) Jonathan A. Ewald et al. PLoS One
- Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
- (2013) Xiaoqi Xie et al. PLoS One
- Mammalian Target of Rapamycin Complex I (mTORC1) Activity in Ras Homologue Enriched in Brain (Rheb)-Deficient Mouse Embryonic Fibroblasts
- (2013) Marlous J. Groenewoud et al. PLoS One
- Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor
- (2013) Swati Sikaria et al. Targeted Oncology
- Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines
- (2013) Rosário Pinto-Leite et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro
- (2013) Marie N. Becker et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses
- (2013) Ghada Soliman Nutrients
- Rheb and mammalian target of rapamycin in mitochondrial homoeostasis
- (2013) M. J. Groenewoud et al. Open Biology
- Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
- (2012) E. Seront et al. ANNALS OF ONCOLOGY
- Updates of mTOR Inhibitors
- (2012) Hongyu Zhou et al. Anti-Cancer Agents in Medicinal Chemistry
- Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma
- (2012) Qian Zhou et al. BIOCHEMICAL PHARMACOLOGY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- The Akt-associated microRNAs
- (2012) Min Xu et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The Intersection Between Aging and Cardiovascular Disease
- (2012) Brian J. North et al. CIRCULATION RESEARCH
- Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
- (2012) E. E. W. Cohen et al. CLINICAL CANCER RESEARCH
- Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
- (2012) Shile Huang et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Temsirolimus: a safety and efficacy review
- (2012) Ronald M. Bukowski Expert Opinion On Drug Safety
- Molecular mechanisms of cisplatin resistance in bladder cancer
- (2012) Ross M Drayton et al. Expert Review of Anticancer Therapy
- Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients
- (2012) Massimiliano Veroux et al. Expert Review of Anticancer Therapy
- Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation
- (2012) Céline Chu et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Antitumor Effects of Rapamycin in Pancreatic Cancer Cells by Inducing Apoptosis and Autophagy
- (2012) Zhi-Jun Dai et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The mTOR Signalling Pathway in Human Cancer
- (2012) Helena Pópulo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
- (2012) Lise Willems et al. Current Oncology Reports
- Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
- (2011) Laura R. Pearce et al. BIOCHEMICAL JOURNAL
- Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells
- (2011) Toshiaki Ohara et al. CANCER SCIENCE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
- (2011) E. Chiong et al. CLINICAL CANCER RESEARCH
- Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
- (2011) Arnulf Stenzl et al. EUROPEAN UROLOGY
- The role of LKB1 and AMPK in cellular responses to stress and damage
- (2011) Angela Alexander et al. FEBS LETTERS
- AMP-activated protein kinase--an energy sensor that regulates all aspects of cell function
- (2011) D. G. Hardie GENES & DEVELOPMENT
- Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder
- (2011) Chih-Hao Sun et al. HISTOPATHOLOGY
- The mTOR (Mammalian Target of Rapamycin) Kinase Maintains Integrity of mTOR Complex 2
- (2011) Chien-Hung Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
- (2011) A.-C. Piguet et al. MOLECULAR CANCER THERAPEUTICS
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
- (2011) Roman Nawroth et al. PLoS One
- A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
- (2011) Shujie Yang et al. PLoS One
- Mechanisms of mTOR inhibitor resistance in cancer therapy
- (2011) Jennifer S. Carew et al. Targeted Oncology
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- In vivo and in vitro effects of RAD001 on bladder cancer
- (2011) Carmen Vasconcelos-Nóbrega et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma
- (2010) Donna E. Hansel et al. AMERICAN JOURNAL OF PATHOLOGY
- Structural Analysis and Functional Implications of the Negative mTORC1 Regulator REDD1,
- (2010) Silvia Vega-Rubin-de-Celis et al. BIOCHEMISTRY
- Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy
- (2010) Andrew Y. Choo et al. CELL CYCLE
- The Complexes of Mammalian Target of Rapamycin
- (2010) Hongyu Zhou et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Amino Acids Activate Mammalian Target of Rapamycin Complex 2 (mTORC2) via PI3K/Akt Signaling
- (2010) Irantzu Tato et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
- (2010) Kathryn G. Foster et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
- (2010) Christina Barbara Ching et al. LABORATORY INVESTIGATION
- mTORC1 signaling: what we still don't know
- (2010) X. Wang et al. Journal of Molecular Cell Biology
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
- (2009) Margaret A. Knowles et al. CANCER AND METASTASIS REVIEWS
- Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer
- (2009) C. M. Seager et al. Cancer Prevention Research
- Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk
- (2009) Meng Chen et al. CARCINOGENESIS
- Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
- (2009) F. M. Platt et al. CLINICAL CANCER RESEARCH
- Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
- (2009) Bas W.G. van Rhijn et al. EUROPEAN UROLOGY
- Inactivation of p53 and Pten promotes invasive bladder cancer
- (2009) A. M. Puzio-Kuter et al. GENES & DEVELOPMENT
- The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
- (2009) Brigette B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of sirolimus on urinary bladder cancer T24 cell line
- (2009) Rosario Pinto-Leite et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Bladder cancer
- (2009) Donald S Kaufman et al. LANCET
- Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
- (2009) Holger Gerullis et al. MEDICAL ONCOLOGY
- mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling
- (2009) L.-A. Julien et al. MOLECULAR AND CELLULAR BIOLOGY
- TOR complex 2: a signaling pathway of its own
- (2009) Nadine Cybulski et al. TRENDS IN BIOCHEMICAL SCIENCES
- The present and future burden of urinary bladder cancer in the world
- (2009) Martine Ploeg et al. WORLD JOURNAL OF UROLOGY
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
- (2008) B. Shor et al. CANCER RESEARCH
- Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.
- (2008) Jorge A. Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Antiproliferative and Overadditive Effects of Rapamycin and FTY720 in Pancreatic Cancer Cells In Vitro
- (2008) Y. Shen et al. TRANSPLANTATION PROCEEDINGS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now